Gilde Healthcare Establishes 6.57% Stake in SpyGlass Pharma Post-IPO
Summary
Gilde Healthcare Holding B.V. and its affiliates reported a 6.57% beneficial ownership in SpyGlass Pharma, Inc. following the company's initial public offering, including a $5 million purchase in the offering.
Key Events
-
Establishes Significant Stake
Gilde Healthcare Holding B.V. and its affiliates reported beneficial ownership of 2,187,513 shares, representing 6.57% of SpyGlass Pharma's common stock.
-
IPO-Related Investment
The stake includes the conversion of Series D preferred stock and an additional $5 million purchase of common stock at $16.00 per share during the company's initial public offering on February 9, 2026.
-
Board Representation
Geoff Pardo, a partner at Gilde Healthcare, serves on the board of directors, indicating active involvement and oversight.
Analysis
This Schedule 13D filing indicates that Gilde Healthcare, a venture capital firm, has established a significant 6.57% beneficial ownership in SpyGlass Pharma, Inc. following its recent initial public offering. The firm converted its Series D preferred stock into common shares and made an additional $5 million purchase of common stock in the IPO at $16.00 per share. This substantial stake, coupled with a partner serving on the board, signals strong institutional confidence in the company's prospects, especially as the stock trades near its 52-week high. This filing aligns with a cluster of other significant insider purchases reported this week, reinforcing positive sentiment around the company's market debut.
At the time of this filing, SGP was trading at $28.22 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $940.2M. The 52-week trading range was $24.71 to $29.47. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.